Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Bombay Biosyntex Chemicals Private Limit Ed, was an unlisted private company incorporated on 25 February, 1977. It is classified as a private limited company and is located in , Maharashtra. It's authorized share capital was INR 5.00 lac and the total paid-up capital was INR 1.00 lac.
The current status of Bombay Biosyntex Chemicals Private Limit Ed is - Amalgamated.
Read more
This action will use 1 of your credits. Are you sure you want to go ahead?
** All rupee values in INR crores. Based on March 2024 numbers.
Tofler currently has no financial reports
for this company due to a lack of available
information. This may be because the company
is dormant or closed (see company status)
or because it was formed only recently
(check the incorporation date) and financial data
is not yet available.
You can view basic information by scrolling through the page.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
State | Type | Address |
---|
Read more
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Networth | |||||
Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Solvency + | |||||
Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Liquidity + | |||||
Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Performance | |||||
Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Return + | |||||
Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Efficiency + | |||||
Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Working Capital | |||||
Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Designation | Name | DIN/PAN | Tenure |
---|---|---|---|
Director | Maneesh Ramakant Sapte | 00020450 | 21 years |
Director | Vinay Ramakant Sapte | 00135085 | 40 years |
Name | Status | Paid up Capital | Common Directors | Address |
---|---|---|---|---|
SVIZERA PHARMA PRIVATE LIMITED |
Active
|
10.0 L | 2 | Maharashtra |
SERVAC PHARMA (I) PRIVATE LIMITED |
Active
|
1.0 L | 2 | Maharashtra |
PHAARMASIA LIMITED |
Active
|
6.8 Cr | 2 | Telangana |
SHANBAG STORAGE AND SERVICES PRIVATE LIM ITED |
Amalgamated
|
25.0 L | 2 | Maharashtra |
ADHRIT EDUCATION PRIVATE LIMITED |
Converted to LLP
|
1.0 L | 2 | Maharashtra |
PURE HEALTH PRODUCTS PRIVATE LIMITED |
Active
|
45.5 L | 2 | Maharashtra |
MANTECH COUNTING AND SYSTEMS PRIVATE LIMITED |
Converted to LLP
|
3.8 L | 2 | Maharashtra |
SVIZERA PHARMATECH PRIVATE LIMITED |
Strike Off
|
0.0 | 2 | Maharashtra |
SVIZERA LABS PRIVATE LIMITED |
Active
|
2.8 Cr | 2 | Maharashtra |
SVIZERA HEALTH REMEDIES PRIVATE LIMITED |
Converted to LLP
|
99.2 L | 2 | Maharashtra |
HERITAGE LABORATORIES PRIVATE LIMITED |
Amalgamated
|
24.6 L | 2 | Himachal Pradesh |
SHANBAG STORAGE AND SERVICES PRIVATE LIMITED |
Active
|
1.0 L | 2 | Maharashtra |
ADHRIT EDUCATION LLP |
Active
|
1.0 L | 2 | Maharashtra |
SVIZERA HEALTH REMEDIES LLP |
Active
|
99.2 L | 2 | Maharashtra |
PHARMANOVA SPECIALTIES PRIVATE LIMITED |
Active
|
5.2 Cr | 2 | Maharashtra |
MANEESH PHARMACEUTICALS LIMITED |
Active
|
28.1 Cr | 2 | Maharashtra |
ERGOS LIFE SCIENCES PRIVATE LIMITED |
Active
|
61.0 Cr | 1 | Maharashtra |
FAROMED LIFESCIENCES LLP |
Active
|
1.0 L | 1 | Maharashtra |
MANTECH COUNTING AND SYSTEMS LLP |
Active
|
3.8 L | 1 | Maharashtra |
The incorporation date of BOMBAY BIOSYNTEX CHEMICALS PRIVATE LIMIT ED is 25 February, 1977
The authorized share capital of BOMBAY BIOSYNTEX CHEMICALS PRIVATE LIMIT ED is INR ₹ 5.0 L.
The paid-up capital of BOMBAY BIOSYNTEX CHEMICALS PRIVATE LIMIT ED is INR ₹ 1.0 L.
The registered address of BOMBAY BIOSYNTEX CHEMICALS PRIVATE LIMIT ED is 23/24, KALPATARU COURT, DR. C. GIDWANI MARG, CHEMBUR MUMBAI Mumbai City Maharashtra - 400074
The CIN number of BOMBAY BIOSYNTEX CHEMICALS PRIVATE LIMIT ED is U24230MH1977PTC019510.